Zacks Research Has Bullish Estimate for BMY FY2026 Earnings

Bristol Myers Squibb Company (NYSE:BMY) – Analysts at Zacks Research increased their FY2026 earnings per share (EPS) estimates for shares of Bristol Myers Squibb in a research report issued on Thursday, August 13th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings per share of $6.85 for the year, up from their prior estimate of $6.27. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.95 per share. Zacks Research also issued estimates for Bristol Myers Squibb’s FY2028 earnings at $5.11 EPS.

Several other equities research analysts have also recently commented on BMY. Truist Financial reaffirmed a “buy” rating and issued a $70.00 target price (up from $65.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Royal Bank Of Canada boosted their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a research report on Friday, July 31st. Weiss Ratings raised shares of Bristol Myers Squibb from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, July 30th. Guggenheim restated a “buy” rating and issued a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Finally, UBS Group cut Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $66.06.

Bristol Myers Squibb Stock Performance

NYSE:BMY opened at $66.07 on Monday. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The firm’s fifty day simple moving average is $59.94 and its 200 day simple moving average is $59.14. The stock has a market cap of $134.97 billion, a P/E ratio of 14.55, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb has a twelve month low of $42.52 and a twelve month high of $68.10.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter in the prior year, the company earned $1.46 earnings per share. The firm’s revenue for the quarter was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Brighton Jones LLC boosted its stake in Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after acquiring an additional 4,935 shares in the last quarter. Sivia Capital Partners LLC lifted its holdings in shares of Bristol Myers Squibb by 59.4% during the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after purchasing an additional 2,786 shares during the last quarter. United Bank lifted its holdings in shares of Bristol Myers Squibb by 15.0% during the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock valued at $1,164,000 after purchasing an additional 3,277 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth approximately $221,000. Finally, Nebula Research & Development LLC purchased a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth approximately $405,000. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.8%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.